Literature DB >> 10549508

Topotecan as a 21-day continuous infusion with accelerated 3D-conformal radiation therapy for patients with glioblastoma.

G G Grabenbauer1, M Buchfelder, U Schrell, R Fahlbusch, R Sauer, H J Staab.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1999        PMID： 10549508     DOI： 10.1159/000061220

Source DB:  PubMed          Journal:  Front Radiat Ther Oncol        ISSN： 0071-9676


× No keyword cloud information.
  2 in total

1.  Topotecan can compensate for protracted radiation treatment time effects in high grade glioma xenografts.

Authors:  Sophie Pinel; Pascal Chastagner; Jean-Louis Merlin; Christian Marchal; Alphonse Taghian; Muriel Barberi-Heyob
Journal:  J Neurooncol       Date:  2006-01       Impact factor: 4.130

2.  Phase I study of topotecan in combination with concurrent radiotherapy in adults with glioblastoma.

Authors:  Thierry Lesimple; Mohammed B Hassel; Daniel Gédouin; Eric Seigneuret; Béatrice Carsin; Abderrahmane Hamlat; Laurent Riffaud; Hélène Simon; Jean P Malhaire; Yvon Guégan
Journal:  J Neurooncol       Date:  2003-11       Impact factor: 4.130
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.